Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. [Review]
Citation: Journal of the American Academy of Dermatology. 83(4):1150-1159, 2020 Oct.PMID: 32569797Institution: MedStar Washington Hospital CenterDepartment: DermatologyForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Coronavirus Infections/pc [Prevention & Control] | *Dermatology/st [Standards] | *Immunosuppression/st [Standards] | *Pandemics/pc [Prevention & Control] | *Pneumonia, Viral/pc [Prevention & Control] | *Practice Guidelines as Topic | *Skin Diseases/th [Therapy] | Advisory Committees/st [Standards] | Betacoronavirus/im [Immunology] | Betacoronavirus/py [Pathogenicity] | Clinical Decision-Making | Coronavirus Infections/ep [Epidemiology] | Coronavirus Infections/im [Immunology] | Coronavirus Infections/vi [Virology] | Decision Making, Shared | Dermatologists/st [Standards] | Dermatology/mt [Methods] | Disease Susceptibility/im [Immunology] | Hospitalists/st [Standards] | Humans | Immunosuppression/ae [Adverse Effects] | Immunosuppression/mt [Methods] | Interdisciplinary Communication | Pneumonia, Viral/ep [Epidemiology] | Pneumonia, Viral/im [Immunology] | Pneumonia, Viral/vi [Virology] | Skin Diseases/im [Immunology] | Societies, Medical/st [Standards] | Symptom Flare UpYear: 2020ISSN:- 0190-9622
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 32569797 | Available | 32569797 |
Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the SARS-CoV-2 pandemic. Though the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in COVID-19 are scarce. This article reviews and offers guidance based upon currently available safety data, and the most recent COVID-19 outcome data, in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasize a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic. Copyright (c) 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
English